Penile revascularization surgery for arteriogenic erectile dysfunction: the long‐term efficacy rate calculated by survival analysis
Authors: Kawanishi Yasuo , Kimura Kazunori , Nakanishi Ryouichi , Kojima Keiji , Numata Akira 
Published: August 2004

Authors from Japan describe their results with penile revascularization in patients who had arteriogenic erectile dysfunction. They recommend that this type of surgery is most suited to younger patients, and suggested that attention be paid to the long‐term outcome and the long‐term adverse events.

OBJECTIVE

To determine the subjective and objective outcomes (by survival analysis) after penile revascularization surgery in patients with arteriogenic erectile dysfunction (ED), selected by established strict criteria.

PATIENTS AND METHODS

The study included 51 patients diagnosed with arteriogenic ED caused by localised arterial lesions and who had microscopic penile revascularization surgery between January 1996 and March 2002. Before surgery, all patients had a full examination, including a medical and sexual history, laboratory testing, intracavernosal pharmacological tests, colour Doppler ultrasonography (CDU), pharmacodynamic infusion cavernosometry and cavernosography, and digital subtraction angiography (DSA). Penile revascularization surgery was indicated only in patients aged <50 years and with no history of diabetes mellitus, hypertension or hyperlipidaemia. When there were communicating branches between the dorsal and cavernosal arteries, Hauri's procedure was used; when there were none or there was no evidence for them on both CDU and DSA because of severe narrowing or obstruction in the proximal common penile artery, the Furlow‐Fisher modification of the Virag V procedure (FFV5) was used. The patency of the neo‐arterial blood flow was assessed by CDU and effective rates calculated using the Kaplan‐Meier method. The efficacy rate was recalculated whenever there was a recurrence. When occlusion of the neo‐arterial blood was confirmed by CDU the date of occlusion was set as that midway between the last examination showing patency of the donor vessel and the latest examination indicating the occlusion. The patency period was the number of days from surgery to the date of occlusion.

RESULTS

Of the 51 patients, 26 had Hauri's and 23 the FFV5 procedure (median age 32 years, range 21–49); in two patients with a previous pelvic fracture surgery was not possible because of scar formation in the dorsal area at the base of the penis. The mean (sd) subjectively estimated efficacy rate was 85.9 (6.3)% after 3 and 67.5 (10.7)% after 5 years of follow‐up. The duration at 75% efficacy was 41.0 (5.6) months. The objectively estimated efficacy rate was 84.9 (7.3)% at 3 and 65.5 (13.5)% after 5 years of follow‐up. The duration at 75% patency was 42.4 (9.5) months, and at 50% was 60.6 (19.4) months. There was no significant difference in subjective outcome between the FFV5 and Hauri procedures (P = 0.38, log rank test) and none objective outcome after surgery (P = 0.19, log rank test). Thirteen of the 18 patients in the Hauri group had venous dilatation in the deep dorsal, obturator, prostatic and the internal iliac veins. There were operative complications in four patients (hyperaemia of the glans in two, and one each with haemorrhage from the anastomosis site and scar contracture).

CONCLUSIONS

The long‐term efficacy rates (by the Kaplan‐Meier method) of the Hauri and FFV5 procedures were both acceptable. The selection criteria gave acceptable outcomes from both procedures. Penile revascularization surgery is a treatment suitable only for young men and therefore attention must be given not only to the long‐term outcome but also to long‐term adverse events.